Guidelines for Anticoagulation Therapy for Secondary Prevention After Deep Vein Thrombosis
PROLONG: D-Dimer Testing to Determine Duration of Anticoagulation5
June 2011
So the use of fibrin D-Dimer has been assessed in a prospective trial called the PROLONG trial in this slide.
More than 600 patients with idiopathic venous thrombosis were treated for their thrombus for 3 months and then their warfarin was stopped. One month later, they had fibrin D-Dimer testing. If the D-Dimer was normal, then they were left off of warfarin therapy. If it was abnormal, then they were randomized to either to resume warfarin or to remain off of warfarin therapy.
Testing Duration of Anticoagulation5 |
Jump to section:
- Introduction
- Independent Risk Factors for Venous Thromboembolism1
- Thrombophilia Testing
- ACCP Treatment Duration Guidelines2
- Aggressive Thrombophilia2
- Case
- Case
- Recurrence Rate
- ACCP Treatment Duration Guidelines3
- D-Dimer Levels and Risk of Recurrent Venous Thromboembolism4
- PROLONG: D-Dimer Testing to Determine Duration of Anticoagulation5
- PROLONG: D-Dimer Testing to Determine Duration of Anticoagulation5
- Idiopathic VTE
- Residual Vein Thrombosis (RVT) to Assess Optimal Management of DVT: DACUS Study6
- Residual Vein Thrombosis (RVT) to Determine Duration of Anticoagulation6
- Recurrent VTE by RVT at 3 Months: DACUS Study6
- Non-compressed vs. Compressed
- Idiopathic DVT: Take Home Point
- Case (revisited)
- Case (revisited)
- Mortality Risk
- Cumulative Recurrence of DVT vs PE After Incident DVT
- Cumulative Recurrence of DVT vs PE After Incident PE
- Independent Predictors of Death within 7 Days of Venous Thromboembolism Recurrence
- Idiopathic PE – Take Home Points
- References
- Clinical and Laboratory Update in Thrombosis and Anticoagulation
- Questions?
External
link
PDF
document
Excel
document
Word
document